全膝关节置换术后伸膝装置重建:同种异体移植物或合成补片均伴高感染、翻修和伸膝迟滞风险
单中心回顾性分析78例全膝关节置换术后伸膝装置重建患者,5年无翻修或伸膝迟滞>30°生存率为54%,同种异体移植物与合成补片间无差异;2年无假体周围感染生存率为81%,17例感染中4例最终关节融合、3例股骨截肢。
要点
- 5年无翻修或伸膝迟滞>30°生存率54%(95%CI 44%–66%),同种异体移植物与补片无差异。
- 2年无假体周围感染生存率81%(95%CI 73%–90%),两种技术间无差异。
- 17例假体周围感染中4例关节融合、3例股骨截肢。
核心结论
- 同种异体移植物和合成补片重建常遗留持续性肢体功能障碍,部分患者发生假体周围感染并接受挽救手术。
- 作者认为患者和外科医生在决定治疗时应充分知晓潜在不良结局并进行风险-获益分析。
- 作者提出需要未来研究确定改善重建耐久性的方案,并明确延长预防性抗生素治疗等措施是否有助于降低假体周围感染风险。
研究设计与样本
- 回顾性分析2008年4月至2020年12月单中心123例全膝关节置换术后伸膝装置重建患者,37%(45例)因随访不足2年、近5年未随访、未达研究终点或行初次修复而排除,最终分析63%(78例)。
- 研究期间,当存在髌腱或股四头肌腱急性或慢性断裂,或髌骨骨折导致伸膝迟滞时考虑伸膝装置手术。
- 使用补片还是同种异体移植物主要取决于外科医生对两种技术的经验和熟悉程度。
- 采用Kaplan-Meier生存分析,终点为伸膝迟滞>30°或重建翻修以及假体周围感染。
- 平均随访时间5.3±3.2年;证据等级为III级治疗性研究。
主要发现
- 5年无翻修或复发性伸膝迟滞生存率为54%(95%CI 44%–66%)。
- 5年时,同种异体移植物组与补片组无翻修或复发性伸膝迟滞生存率无差异(52%[95%CI 40%–68%] vs 57%[95%CI 41%–78%];p=0.99)。
- 2年无假体周围感染生存率为81%(95%CI 73%–90%)。
- 2年时,同种异体移植物组与补片组无假体周围感染生存率无差异(79%[95%CI 69%–92%] vs 83%[95%CI 71%–98%];p=0.75)。
- 17例发生假体周围感染的患者中,4例最终行关节融合,另有3例行股骨截肢。
关键数值与推荐
- 5年无翻修或伸膝迟滞>30°生存率:总体54%(95%CI 44%–66%)。
- 5年无翻修或伸膝迟滞>30°生存率:同种异体移植物组52%(95%CI 40%–68%)vs 补片组57%(95%CI 41%–78%),p=0.99。
- 2年无假体周围感染生存率:总体81%(95%CI 73%–90%)。
- 2年无假体周围感染生存率:同种异体移植物组79%(95%CI 69%–92%)vs 补片组83%(95%CI 71%–98%),p=0.75。
临床怎么用
- 原文未据此给出推荐。
局限性
- 37%(45例)患者因随访不足2年、近5年未随访、未达研究终点或行初次修复而无法分析。
- 作者提出需要未来研究确定改善重建耐久性的方案,并明确延长预防性抗生素治疗等措施是否有助于降低假体周围感染风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extensor mechanism disruption is a devastating complication after TKA. Extensor mechanism reconstruction can be performed using an allograft or synthetic mesh. Recent studies have disagreed about the durability of these reconstructions. Evaluating a larger series of reconstructions that use current popular techniques and principles provides information to guide patient and surgeon expectations while bringing to light the potential fate of patients who experience an infection postoperatively. QUESTIONS/PURPOSES: (1) What was the 5-year survival free of repeat revision surgery or persistent extensor lag of more than 30° after allograft or synthetic mesh reconstruction of extensor mechanism disruptions after TKA, and did this differ between techniques? (2) What was the 5-year survival free of infection after allograft or mesh reconstruction, and what proportion of those patients experienced a secondary severe complication (arthrodesis or amputation)? METHODS: Between April 2008 and December 2020, 123 patients underwent extensor mechanism reconstruction after TKA at one center. Of those, 37% (45) were lost to follow-up before 2 years, had not been seen in the past 5 years, did not reach a study endpoint (repeat revision or extensor lag > 30°) before that time, or underwent primary repair and thus could not be analyzed, leaving 63% (78) for analysis here. During the study period, we considered extensor mechanism surgery when acute or chronic disruption of the patellar or quadriceps tendon was present or there was a fracture of the patella resulting in extensor lag. The decision to use either mesh or an allograft largely depended on surgeon experience and familiarity with either technique. We collected patient demographics, operative details (location of disruption and presence of a hinged prosthesis), subsequent periprosthetic joint infection (PJI), and postoperative SF-12 and Knee Injury and Osteoarthritis Outcome Score, Joint Replacement, scores. We used Kaplan-Meier survivorship analysis, with endpoints of extensor lag more than 30° or revision of the reconstruction and PJI. The mean follow-up duration was 5.3 ± 3.2 years. RESULTS: Survivorship free from revision or recurrent extensor lag was 54% (95% CI 44% to 66%) at 5 years. There was no difference between those undergoing reconstruction with allografts and those with mesh in terms of survivorship free from those endpoints at that timepoint (52% [95% CI 40% to 68%] versus 57% [95 CI% 41 to 78%]; p = 0.99). Survivorship free from PJI was 81% (95% CI 73% to 90%) at 2 years. There was no difference between those with allografts and those with mesh in terms of survivorship free from PJI at that timepoint (79% [95% CI 69% to 92%] versus 83% [95% CI 71% to 98%]; p = 0.75). Of the 17 patients who experienced PJI, four ultimately underwent arthrodesis and three more underwent transfemoral amputation. CONCLUSION: Allograft and synthetic mesh reconstructions commonly left patients with persistent limb dysfunction, while several patients had PJI and some underwent salvage procedures. Although improvements have been made with regard to treating extensor mechanism disruptions, patients and surgeons should be well aware of the potential adverse outcomes when determining management and use these findings to conduct risk-benefit analyses. There is a need for future studies to identify protocols that improve the durability of reconstructions and to determine whether interventions such as prolonged prophylactic antibiotic therapy have a role in minimizing the risk of PJI. LEVEL OF EVIDENCE: Level III, therapeutic study.
引用
- Baker CM, Goh GS, Qadiri Q, et al. Allograft or Synthetic Mesh Extensor Mechanism Reconstruction After TKA Carries a High Risk of Infection, Revision, and Extensor Lag. Clin Orthop Relat Res. 2023. PMID: 37678244. doi:10.1097/CORR.0000000000002826
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。